| Oct 8 |
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
|
| Sep 30 |
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
|
| Sep 23 |
Opthea joins S&P/ASX 300 index
|
| Sep 23 |
Opthea Joins the S&P/ASX 300 Index
|
| Sep 20 |
Opthea (OPT): Biopharma Innovator on the Verge of a Wet AMD Treatment Revolution
|
| Sep 18 |
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
|
| Sep 10 |
Exploring 3 High Growth Tech Stocks in Australia
|
| Sep 10 |
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
|
| Sep 5 |
Opthea appoints Daniel Geffken as interim CFO
|
| Sep 5 |
Opthea Announces Executive Leadership Changes and Senior Hires
|
